Safety Study of a Disrupted Adenovirus (Ad) Serotype Cocaine Vaccine for Cocaine-dependent Individuals

• ClinicalTrials.gov Identifier: NCT02455479
• Recruitment Status: Recruiting
• First Posted: May 27, 2015
• Last Update Posted: December 14, 2023
• Sponsor: Weill Medical College of Cornell University
• Collaborator: National Institute on Drug Abuse (NIDA)
• Information provided by (Responsible Party): Weill Medical College of Cornell University

Study Description

Brief Summary:

The purpose of this study is to assess the safety and preliminary efficacy of an anti-cocaine vaccine called dAd5GNE in cocaine-dependent individuals. It uses the concept of a vaccine to treat the neurological effects of cocaine by evoking "immunity" to prevent the effects of cocaine on the brain.

Condition or disease	Intervention/treatment	Phase
Cocaine Dependence	Biological: dAd5GNE Vaccine; Biological: Placebo	Phase 1

Detailed Description:

This is a Phase I dose-ranging, placebo-controlled, double blind study assessing the safety and preliminary efficacy of an anti-cocaine vaccine called "dAd5GNE vaccine". The vaccine is designed to prevent cocaine from reaching the brain. The vaccine is comprised of GNE, a cocaine-like molecule that is linked to the capsid protein of a disrupted serotype 5 adenovirus. The vaccine is used to evoke "immunity" to prevent cocaine from reaching the brain. The vaccine evokes an immune system response and stimulates the creation of anti-cocaine antibodies. The antibodies bind to the cocaine molecules when a person takes cocaine and prevents the cocaine molecules from reaching the brain. This cocaine-antibody complex is not able to cross the blood brain barrier and thus eliminates the effects of cocaine on the brain, as seen in pre-clinical studies done by our group. In mice, rats and nonhuman primates, this vaccine evoked a persistent, high titer, high affinity IgG anti-cocaine antibody response. The pre-clinical studies conducted establish efficacy for high anti-cocaine antibody titers. The immunity sequesters parenterally administered cocaine in the blood, in mice, rats and nonhuman primates (Appendix I-III).

For each subject, the study will take place over a period of 32 weeks from the time of the first vaccine administration, and will enroll cocaine addicts, as defined by the Diagnostic and Statistical Manual of Mental Disorders, 5th edition, Text Revisions (DSM-V-TR).

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 150 participants
• Allocation: Randomized
• Intervention Model: Sequential Assignment
• Masking: Triple (Participant, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: Phase I Randomized, Double-blind, Placebo Control Study for an Anti-cocaine Vaccine
• Actual Study Start Date: June 26, 2012
• Estimated Primary Completion Date: December 2024
• Estimated Study Completion Date: June 2025

Arms and Interventions

Arm	Intervention/treatment
Cohort 1: 100µg; Subjects will receive 100µg dAd5GNE vaccine or placebo at weeks 0, 4, 8, 12, 16 and 20.	Biological: dAd5GNE Vaccine; dAd5GNE Vaccine or Placebo dAd5GNE Vaccine; Biological: Placebo; dAd5GNE Vaccine or Placebo dAd5GNE Vaccine
Cohort 2: 316 µg; Subjects will receive 316 µg dAd5GNE vaccine or placebo at weeks 0, 4, 8, 12, 16 and 20.	Biological: dAd5GNE Vaccine; dAd5GNE Vaccine or Placebo dAd5GNE Vaccine; Biological: Placebo; dAd5GNE Vaccine or Placebo dAd5GNE Vaccine
Cohort 3: 1000µg; Subjects will receive 1000 µg dAd5GNE vaccine or placebo at weeks 0, 4, 8, 12, 16 and 20.	Biological: dAd5GNE Vaccine; dAd5GNE Vaccine or Placebo dAd5GNE Vaccine; Biological: Placebo; dAd5GNE Vaccine or Placebo dAd5GNE Vaccine

Outcome Measures

Primary Outcome Measures :

1. Safety of dAd5GNE vaccine [ Time Frame: 32 weeks ]
   The primary endpoint is to establish the safety of dAd5GNE vaccine using general safety parameters, which includes a general assessment.
2. Safety of dAd5GNE vaccine [ Time Frame: 32 weeks ]
   The primary endpoint is to establish the safety of dAd5GNE vaccine using general safety parameters, which includes a blood test.
3. Safety of dAd5GNE vaccine [ Time Frame: 32 weeks ]
   The primary endpoint is to establish the safety of dAd5GNE vaccine using general safety parameters, which includes urinalysis.
4. Safety of dAd5GNE vaccine [ Time Frame: 32 weeks ]
   The primary endpoint is to establish the safety of dAd5GNE vaccine using general safety parameters, which includes chest x-ray.
5. Safety of dAd5GNE vaccine [ Time Frame: 32 weeks ]
   The primary endpoint is to establish the safety of dAd5GNE vaccine using general safety parameters, which includes ophthalmology exam.
6. Safety of dAd5GNE vaccine [ Time Frame: 32 weeks ]
   The primary endpoint is to establish the safety of dAd5GNE vaccine using general safety parameters, which includes EKG.

Secondary Outcome Measures :

1. Urine cocaine metabolites [ Time Frame: 32 weeks ]
   Urine will be tested for benzoylecgonine (BE). The accepted value for a positive urine cocaine is urine BE of ≥ 300 ng/mL.
2. Anti-cocaine antibody levels over time [ Time Frame: 32 weeks ]
   The primary endpoint is average cocaine titers (week 10 - week 22) > 4.0 x 105 titer units.

Other Outcome Measures:

1. For Information Only [ Time Frame: 32 weeks ]
   Anti-cocaine antibody subtypes, affinity, and specificity
2. For Information Only [ Time Frame: 32 weeks ]
   Anti-Ad5 antibodies
3. For Information Only [ Time Frame: 32 weeks ]
   Cocaine craving self-report
4. For Information Only [ Time Frame: 32 weeks ]
   Timeline followback (TLFB) drug use calendar

Eligibility Criteria

• Ages Eligible for Study: 21 Years to 69 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Accrual will be random, with no bias as to gender or racial/ethnic group. Because the accrual process will be random, it is possible that there may be differences in the proportion of males and females, and racial/ethnic groups among the study individuals. All subjects will be concurrently participating in behavioral therapy programs run by Dr. Beeder's clinical team. Each case will be reviewed with the Eligibility Committee, comprised of three investigators other than the PI, to determine eligibility. The Principal Investigator will not participate in this process.

All subjects must fulfill all inclusion criteria and none of the exclusion criteria in order to participate in this study.

Inclusion Criteria:

1. All subjects should be able to provide informed consent.
2. Must provide HIV informed consent.
3. Males and females, 21- 69 years of age.
4. Individuals that have been diagnosed with a cocaine use disorder according to DSM-V-TR criteria, with documented evidence of cocaine use within the past 60 days and have previously used an average of 1 to 10 grams of powdered and/or crack cocaine (via insufflation or smoking only) per week. Any prior 1 to 4 month period of cocaine abstinence in the past year will be excluded when calculating average cocaine use to evaluate study eligibility.

6. Fertile males and females must agree to use adequate forms of contraception for the duration of the entire study.

7. Body weight > 45 kg.

Exclusion Criteria:

1. Individuals not deemed in good overall health by the investigator.
2. Diagnosed history of severe psychotic disorders.
3. Abnormal EKG at screening with changes consistent with cardiac disease.
4. History of significant cardiovascular disease, hypertension, prior myocardial infarction and/or cerebrovascular event.
5. Individuals who are currently on beta-blockers.
6. Physical signs or laboratory values suggestive of systemic disorders.
7. History of attempted suicide, as assessed by Columbia-Suicide Severity Rating Scale (C-SSRS) and/or committed homicide.
8. History of diagnosed obsessive compulsive disorder (OCD).
9. Known allergy to soy.
10. Individuals who are currently taking alprazolam (Xanax) or ziprasidone (Geodon).
11. Evidence of active infection of any types, including COVID-19, or positive for human immunodeficiency virus (HIV).
12. Historical or current use of immunomodulators or immunosuppressants <5 years prior to screening.
13. Receipt of blood within 3 months of screening.
14. Females who are pregnant or nursing.
15. Concurrent participation in any other FDA approved Investigational New Drug.
16. Abnormal liver function (transaminases greater than 2x the upper limit of normal values)
17. eGFR <30 mL/min/1.73 m2

18. Severe substance use disorder based on DSM-V-TR criteria (excluding cocaine, nicotine, caffeine, alcohol, marijuana and opiates prescribed for medication assisted therapy or pain treatment) currently not in remission according to one of the following criteria:

    • Early Full Remission: This specifier is used if none of the criteria for Dependence or Abuse have been met for at least 1 month, but less than 12 months OR
    • Early Partial Remission: This specifier is used if only one or more (but not all) of the criteria for Dependence or Abuse has/have been met for at least 1 month, but less than 12 months. OR
    • Sustained Full Remission: This specifier is used if none of the criteria for Dependence or Abuse have been met at any time during a period of 12 months or longer OR
    • Sustained Partial Remission: This specifier is used if only one or more (but not all) of the criteria for Dependence or Abuse has/have been met for a period of 12 months or longer OR
    • On Agonist Therapy: This specifier is used if the individual is on a prescribed agonist medication, and none of the criteria for Dependence or Abuse has been met for that class of medication for at least the past month (except tolerance to, or withdrawal from, the agonist). This category also applies to those being treated for Dependence using a partial agonist or an agonist/antagonist OR
    • Substance Use Related Disorder (mild) up to two disorders: Patients that are assessed to have mild substance-use-related disorders according to the DSM-V criteria will be allowed to participate in the study as long as the number of the disorder-resulting substances does not exceed two (with the exception of the nicotine, caffeine, alcohol, marijuana and opiates prescribed for medication assisted therapy or pain treatment).
19. History of any seizure disorder.
20. Individuals with history of Guillain-Barré Syndrome.
21. Diagnosis of >2 Substance Use Related Disorders (mild) based on DSM-V- TR criteria (excluding nicotine, caffeine, alcohol, marijuana and opiates prescribed for medication assisted therapy or pain treatment
22. On a prescribed agonist medication, with criteria for dependence or abuse for that class ofmedication for at least the past month (except tolerance to, or withdrawal from, the agonist

Contacts and Locations

Contacts

Contact: Sandra Hyde; 646-962-2672; sah2003@med.cornell.edu

Locations

United States, New York

WCMC Department of Genetic Medicine; Recruiting

New York, New York, United States, 10021

Contact: Sandra Hyde 646-962-2672 sah2003@med.cornell.edu

Contact: Niamh Savage nis2049@med.cornell.edu

Principal Investigator: Ronald Crystal, MD

Sponsors and Collaborators

Weill Medical College of Cornell University

National Institute on Drug Abuse (NIDA)

Investigators

• Principal Investigator: Ronald G Crystal, MD; Weill Medical College of Cornell University

More Information

• Responsible Party: Weill Medical College of Cornell University
• ClinicalTrials.gov Identifier: NCT02455479
• Other Study ID Numbers: 1206012440; U01DA048524 ( U.S. NIH Grant/Contract )
• First Posted: May 27, 2015
• Last Update Posted: December 14, 2023
• Last Verified: December 2023

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Undecided

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Weill Medical College of Cornell University:

cocaine vaccine; cocaine dependence; Cocaine

Additional relevant MeSH terms:

Cocaine-Related Disorders; Substance-Related Disorders; Chemically-Induced Disorders; Mental Disorders